SCHEMBL18770518

SCHEMBL18770518

CC1=NN(c2ccc(Br)cc2)C(=O)C1(C)Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.43
GAA P10253 2/20 0.42
HPGD P15428 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
AMY1A P0DUB6 1/20 0.39
HSD11B1 P28845 2/20 0.38
OPRM1 P35372 1/20 0.37
HSD17B10 Q99714 2/20 0.36
POLB P06746 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16091682 0.85 SMN1; SMN2 (0.59) SMN1; SMN2GAAHPGDMEN1KMT2A
SCHEMBL17290346 0.81 SMN1; SMN2 (0.43) SMN1; SMN2HSD11B1
SCHEMBL18770479 0.78 SMN1; SMN2 (0.40) SMN1; SMN2GAAHPGDMEN1KMT2A
SCHEMBL18770504 0.78 SMN1; SMN2 (0.40) SMN1; SMN2GAAHPGDMEN1KMT2A
SCHEMBL17290779 0.77 SMN1; SMN2 (0.45) SMN1; SMN2GAAHPGDMEN1KMT2A
SCHEMBL17291128 0.77 CES2 (0.40) SMN1; SMN2GAAHPGDMEN1KMT2A
SCHEMBL13660334 0.74 SMN1; SMN2 (0.43) SMN1; SMN2GAAHPGDMEN1KMT2A
SCHEMBL17290450 0.73 MAPT (0.37) SMN1; SMN2GAAHPGDMEN1KMT2A
SCHEMBL17290911 0.70 SMN1; SMN2 (0.41) SMN1; SMN2GAAHPGDMEN1KMT2A
SCHEMBL17295185 0.70 SMN1; SMN2 (0.41) SMN1; SMN2GAAHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108473439-B Pyrazolone derivatives as nitroxyl donors 卡尔迪奥克斯尔制药公司 2022-03-15 CN disclosed
US-10723704-B2 Pyrazolone derivatives as nitroxyl donors CARDIOXYL PHARMACEUTICALS, INC. (US) 2020-07-28 US disclosed
US-20180318308-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS CARDIOXYL PHARMACEUTICALS, INC. 2018-11-08 US disclosed
EP-3365328-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS Cardioxyl Pharmaceuticals, Inc. (US) 2018-08-29 EP disclosed
WO-2017070081-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS CARDIOXYL PHARMACEUTICALS, INC. (US) 2017-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723704-B2 Pyrazolone derivatives as nitroxyl donors TNNI3, PFKP, NOX5 SMN1; SMN2 1078/4885GAA 1354/4885HPGD 19/4885
US-20180318308-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS TNNI3, PFKP, NOX5 SMN1; SMN2 1078/4885GAA 1354/4885HPGD 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.